FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209279647> ?p ?o ?g. }

• W3209279647 endingPage "69" @default.
• W3209279647 startingPage "63" @default.
• W3209279647 abstract "Oligometastatic disease (OMD) represents a spectrum of clinical scenarios and various classification systems have been proposed. Bone-only OMD can occur in patients with advanced prostate cancer and validated decision-making tools are needed to assist patient selection for metastasis-directed therapy. The aim of the present study was to determine the prognostic utility of a classification system for OMD.A retrospective review was conducted of all patients with bone-only oligometastatic prostate cancer treated with stereotactic body radiotherapy (SBRT) since November 2011. SBRT was delivered using CyberKnife® and gantry-based linear accelerator platforms. All patients were classified into oligometastatic states based on the European Society for Radiotherapy and Oncology/European Organisation for Research and Treatment of Cancer (ESTRO/EORTC) classification system. Kaplan-Meier and Cox regression analyses were carried out to determine the prognostic utility of this classification system.In total, 105 patients with 145 osseous metastases were treated over 119 sessions. The median follow-up after SBRT was 23 months (interquartile range 10-39.8). Twelve patients had died after a median time of 31 months. The 3-year metastatic progression-free survival was 23% (95% confidence interval 13-32) and the 3-year overall survival was 88% (95% confidence interval 80-96). Patients in a metachronous oligometastatic state were 4.50 (95% confidence interval 1.19-17.10, P = 0.03) times more likely to experience metastatic progression compared with those with synchronous oligometastases, and 6.69 (95% confidence interval 1.05-42.50, P = 0.04) times more likely to experience any failure. Hazard ratio magnitudes increased for patients in a repeat oligometastatic state. The multivariate model for both metastatic progression-free survival and failure-free survival found prostate-specific antigen doubling time <4 months (P = 0.002; P = 0.05) to independently predict for progression.The ESTRO/EORTC classification of OMD predicts for progression in patients treated with SBRT for bone-only oligometastatic prostate cancer at our institution. Further validation in prospective series over multiple tumour sites is needed. These characterisation factors should be assessed in patients considered for metastasis-directed therapy together with established prognostic features." @default.
• W3209279647 created "2021-11-08" @default.
• W3209279647 creator A5001546536 @default.
• W3209279647 creator A5044687125 @default.
• W3209279647 creator A5050179625 @default.
• W3209279647 creator A5052046023 @default.
• W3209279647 creator A5056223983 @default.
• W3209279647 creator A5056339622 @default.
• W3209279647 creator A5080362183 @default.
• W3209279647 date "2022-01-01" @default.
• W3209279647 modified "2023-09-26" @default.
• W3209279647 title "Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease" @default.
• W3209279647 cites W1992007584 @default.
• W3209279647 cites W2019607817 @default.
• W3209279647 cites W2031688279 @default.
• W3209279647 cites W2127240958 @default.
• W3209279647 cites W2136706275 @default.
• W3209279647 cites W2167331614 @default.
• W3209279647 cites W2299315051 @default.
• W3209279647 cites W2357020384 @default.
• W3209279647 cites W2423859833 @default.
• W3209279647 cites W2498309700 @default.
• W3209279647 cites W2584582525 @default.
• W3209279647 cites W2596956169 @default.
• W3209279647 cites W2664930764 @default.
• W3209279647 cites W2729249879 @default.
• W3209279647 cites W2743350540 @default.
• W3209279647 cites W2761351587 @default.
• W3209279647 cites W2763991661 @default.
• W3209279647 cites W2775321189 @default.
• W3209279647 cites W2790444843 @default.
• W3209279647 cites W2796600021 @default.
• W3209279647 cites W2807085990 @default.
• W3209279647 cites W2895455649 @default.
• W3209279647 cites W2897236707 @default.
• W3209279647 cites W2915324226 @default.
• W3209279647 cites W2939770857 @default.
• W3209279647 cites W2944301866 @default.
• W3209279647 cites W2965638931 @default.
• W3209279647 cites W2972275304 @default.
• W3209279647 cites W2991821398 @default.
• W3209279647 cites W2997721110 @default.
• W3209279647 cites W3012827461 @default.
• W3209279647 cites W3019546741 @default.
• W3209279647 cites W3025293463 @default.
• W3209279647 cites W3091329870 @default.
• W3209279647 cites W4240340450 @default.
• W3209279647 doi "https://doi.org/10.1016/j.clon.2021.10.004" @default.
• W3209279647 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34756755" @default.
• W3209279647 hasPublicationYear "2022" @default.
• W3209279647 type Work @default.
• W3209279647 sameAs 3209279647 @default.
• W3209279647 citedByCount "7" @default.
• W3209279647 countsByYear W32092796472021 @default.
• W3209279647 countsByYear W32092796472022 @default.
• W3209279647 countsByYear W32092796472023 @default.
• W3209279647 crossrefType "journal-article" @default.
• W3209279647 hasAuthorship W3209279647A5001546536 @default.
• W3209279647 hasAuthorship W3209279647A5044687125 @default.
• W3209279647 hasAuthorship W3209279647A5050179625 @default.
• W3209279647 hasAuthorship W3209279647A5052046023 @default.
• W3209279647 hasAuthorship W3209279647A5056223983 @default.
• W3209279647 hasAuthorship W3209279647A5056339622 @default.
• W3209279647 hasAuthorship W3209279647A5080362183 @default.
• W3209279647 hasConcept C119060515 @default.
• W3209279647 hasConcept C121608353 @default.
• W3209279647 hasConcept C126322002 @default.
• W3209279647 hasConcept C143998085 @default.
• W3209279647 hasConcept C167135981 @default.
• W3209279647 hasConcept C2776651944 @default.
• W3209279647 hasConcept C2777783956 @default.
• W3209279647 hasConcept C2779013556 @default.
• W3209279647 hasConcept C2780192828 @default.
• W3209279647 hasConcept C2780387249 @default.
• W3209279647 hasConcept C44249647 @default.
• W3209279647 hasConcept C50382708 @default.
• W3209279647 hasConcept C509974204 @default.
• W3209279647 hasConcept C71924100 @default.
• W3209279647 hasConceptScore W3209279647C119060515 @default.
• W3209279647 hasConceptScore W3209279647C121608353 @default.
• W3209279647 hasConceptScore W3209279647C126322002 @default.
• W3209279647 hasConceptScore W3209279647C143998085 @default.
• W3209279647 hasConceptScore W3209279647C167135981 @default.
• W3209279647 hasConceptScore W3209279647C2776651944 @default.
• W3209279647 hasConceptScore W3209279647C2777783956 @default.
• W3209279647 hasConceptScore W3209279647C2779013556 @default.
• W3209279647 hasConceptScore W3209279647C2780192828 @default.
• W3209279647 hasConceptScore W3209279647C2780387249 @default.
• W3209279647 hasConceptScore W3209279647C44249647 @default.
• W3209279647 hasConceptScore W3209279647C50382708 @default.
• W3209279647 hasConceptScore W3209279647C509974204 @default.
• W3209279647 hasConceptScore W3209279647C71924100 @default.
• W3209279647 hasIssue "1" @default.
• W3209279647 hasLocation W32092796471 @default.
• W3209279647 hasLocation W32092796472 @default.
• W3209279647 hasOpenAccess W3209279647 @default.
• W3209279647 hasPrimaryLocation W32092796471 @default.
• W3209279647 hasRelatedWork W1971665703 @default.

• next